Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use
Authors:
- Maren WernerMWMaren Werner
- Philip PervanPPPhilip Pervan
- Vivian GlückVGVivian Glück
- Florian ZemanFZFlorian Zeman
- Michael KollerMKMichael Koller
- Ralph BurkhardtRBRalph Burkhardt
- Thomas GlückTGThomas Glück
- Jürgen J. WenzelJWJürgen J. Wenzel
- Barbara SchmidtBSBarbara Schmidt
- André GessnerAGAndré Gessner
- David PeterhoffDPDavid Peterhoff
Open Access
- 8 April 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (8) , 1580
Abstract
Serological testing is crucial in detection of previous infection and in monitoring convalescent and vaccine-induced immunity. During the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) pandemic, numerous assay platforms have been developed and marketed for clinical use. Several studies recently compared clinical performance of a limited number of serological tests, but broad comparative evaluation is currently missing. Within this study, a panel of 161 sera from SARS-CoV-2 infected, seasonal CoV-infected and SARS-CoV-2 naïve subjects was enrolled to evaluate 16 ELISA/ECLIA-based and 16 LFA-based tests. Specificities of all ELISA/ECLIA-based assays were acceptable and generally in agreement with the providers’ specifications, but sensitivities were lower as specified. Results of the LFAs were less accurate as compared to the ELISAs, albeit with some exceptions. We found a sporadic unequal immune response for different antigens and thus recommend the use of a nucleocapsid protein (N)- and spike protein (S)-based test combination when maximal sensitivity is necessary. Finally, the quality of the immune response in terms of neutralization should be tested using S-based IgG tests.Keywords
Funding Information
- Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst (Pandemic Responsiveness Fund)
This publication has 27 references indexed in Scilit:
- SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19Infection, 2021
- The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In VitroJournal of Clinical Medicine, 2021
- Neutralizing antibodies targeting SARS-CoV-2 spike proteinStem Cell Research, 2021
- Manufacturing of convalescent plasma of COVID-19 patients: Aspects of qualityPLOS ONE, 2020
- The complexities of SARS-CoV-2 serologyThe Lancet Infectious Diseases, 2020
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapiesNature Microbiology, 2020
- Evaluation of SARS-CoV-2 serology assays reveals a range of test performanceNature Biotechnology, 2020
- A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralizationInfection, 2020
- Analytical and clinical validation of an ELISA for specific SARS‐CoV‐2 IgG, IgA, and IgM antibodiesJournal of Medical Virology, 2020
- Two-sided confidence intervals for the single proportion: comparison of seven methodsStatistics in Medicine, 1998